List view / Grid view
8 September 2014 | By Abbott
A new study suggests a pioneering testing technology could reduce hospital stays by up to eight days and lower annual health care costs for people with serious infections by approximately $2.2 million (€1.5 million / £1.2 million)...
8 September 2014 | By GlaxoSmithKline
GSK presented data at the European Respiratory Society Congress that show blood eosinophil levels may help predict those patients with COPD who will have a greater reduction in exacerbation rates when receiving an inhaled corticosteroid containing regimen...
5 September 2014 | By Merck
Merck announced that the U.S. Food and Drug Administration has approved KEYTRUDA® (pembrolizumab) at a dose of 2 mg/kg every three weeks for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimuma...
5 September 2014 | By Teva Pharmaceutical Industries Ltd
Teva Pharmaceutical Industries Ltd. announces the launch of the generic equivalent to Baraclude® (Entecavir) Tablets, 0.5mg and 1mg, in the United States...
5 September 2014 | By Abbott
Abbott announced that it has received CE Mark for its FreeStyle® Libre Flash Glucose Monitoring System, a revolutionary new glucose sensing technology for people with diabetes...
5 September 2014 | By GlaxoSmithKline
ViiV Healthcare announced that the European Commission has granted marketing authorisation for Triumeq® (dolutegravir 50mg / abacavir 600mg / lamivudine 300mg) tablets...
4 September 2014 | By Andrew Lloyd & Associates
Nosopharm announces its in vitro and in vivo findings for a novel antibacterial class, Odilorhabdins, which has the potential to combat antibiotic resistance...
4 September 2014 | By Roche
Roche announced that Arthur D. Levinson has resigned from the Board of Directors, effective immediately. Arthur D. Levinson made this decision so as to avoid any conflict of interest given his role as Chief Executive Officer at Calico...
4 September 2014 | By Masters
Masters Speciality Pharma signs agreement for the exclusive distribution of Ferriprox® (deferiprone)...
3 September 2014 | By GeNeuro
GeNeuro SA, a pioneer of new therapies for neurology disorders, announced positive results from a one-year, open-label extension of a Phase IIa study...
3 September 2014 | By The University of Nottingham
New research from The University of Nottingham looks set to improve screening for new cancer drugs and drug delivery systems specifically designed for children with brain tumours...
3 September 2014 | By kdm communications
Cresset is pleased to announce that Selvita S.A., a drug discovery company located in Krakow, Poland, has licensed Cresset’s Forge and Spark...
3 September 2014 | By Daiichi Sankyo
Daiichi Sankyo Company, Limited announced data from a subgroup analysis of the phase 3 ENGAGE AF-TIMI 48 study, that explores the relationship between edoxaban dose, concentration and anti-factor Xa activity in patients with non-valvular atrial fibrillation...
3 September 2014 | By Novo Nordisk
The Lancet Diabetes & Endocrinology has published the phase 3a DUAL™ I study investigating IDegLira (insulin degludec/liraglutide; Xultophy®) − once-daily, single injection insulin degludec (Tresiba®▼ ) and liraglutide (Victoza®)...
3 September 2014 | By Boehringer Ingelheim
New data presented indicate that kidney function decline is less pronounced in patients with an irregular heartbeat who are treated with Pradaxa® (dabigatran etexilate) compared to warfarin...
